Choriomon

Quick links to important sections

Choriomon

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Choriomon

This introductory overview defines the core identity, composition, and general purpose of the medicine, strictly adhering to the scope of classification and origin.

Property Description
Active Ingredient Choriogonadotropin Alfa
Form Powder for injection; Solution
Pharmacological Class Gonadotropin Hormone; Luteinizing Hormone (LH) Analog
General Purpose To trigger final egg maturation and ovulation in fertility treatment
Origin Recombinant (synthetic)

Choriogonadotropin Alfa: Identity and Pharmacological Classification

Choriomon is a prescription medicine used in fertility treatments, primarily containing the active ingredient Choriogonadotropin Alfa. This compound is classified as a potent Luteinizing Hormone (LH) Analog within the gonadotropin hormone pharmacological class. This means it is designed to mimic the body's natural LH surge, which is essential for reproduction. The mechanism of Choriogonadotropin Alfa is clinically recognized for its ability to reliably trigger ovulation and support the luteal phase, a crucial step in assisted reproductive technologies. As a single-component product, it is typically administered via subcutaneous injection or intramuscular injection, requiring reconstitution from a powder for injection into an aqueous solution.


Origin and Composition: Recombinant Technology

The active substance, Choriogonadotropin Alfa, is a recombinant glycoprotein hormone, clarifying that it is a synthetic protein produced in a laboratory using advanced Recombinant DNA technology. This technological origin ensures the active ingredient is highly pure and offers predictable biological activity, setting it apart from older, urinary-derived chorionic gonadotropin products (u-hCG). Recombinant hCG ensures higher consistency and purity than naturally derived sources. This feature is a defining characteristic of Choriogonadotropin Alfa products, differentiating them from older preparations that relied on extraction from human urine.


General Purpose: Function in Fertility Treatment

Choriomon's general purpose is to provide the decisive hormonal impulse needed to complete the ovarian cycle in women undergoing controlled ovarian stimulation. Acting as the final surge signal, it facilitates final follicular maturation and the controlled induction of ovulation (the release of the mature egg). It assists in ensuring the precise timing of egg release, which is necessary for various procedures used to address specific types of infertility.

Regulatory References

  1. MedlinePlus Reference

What side effects are possible with Choriomon?

Possible Side Effects and Safety Information

Adverse reactions associated with Choriogonadotropin Alfa are classified by government regulatory documents according to their frequency and the physiological systems affected. These official safety statements define the expected risk profile of the medicine.

Frequency-Classified Adverse Reactions

Frequency Category Representative Adverse Reactions
Very Common (ge 1/10) Injection site pain, Headache, Nausea, Abdominal pain.
Common (ge 1/100 to < 1/10) Vomiting, Abdominal distension, Ovarian cyst, Mild or Moderate Ovarian Hyperstimulation Syndrome (OHSS), Tiredness, Injection site reactions.
Uncommon (ge 1/1,000 to < 1/100) Severe OHSS, Depression, Irritability, Restlessness, Breast pain.
Very Rare (< 1/10,000) Thromboembolic events, Hypersensitivity reactions (including anaphylaxis).

Serious Adverse Reactions

The most clinically significant adverse reaction documented in official labeling is Severe Ovarian Hyperstimulation Syndrome (OHSS). This condition can lead to complications such as ascites, pleural effusions, acute pulmonary distress, and transient liver function abnormalities. The product labeling also cites a risk of thromboembolic events, particularly arterial events, which are more likely in the context of severe OHSS.

Safety Considerations and Restrictions

Time-Related Patterns: OHSS often occurs after treatment completion, typically reaching maximum severity around seven to ten days following administration. The drug may interfere for up to 10 days with immunological pregnancy tests, potentially causing a false positive result.

Contraindications: Choriogonadotropin Alfa is formally restricted from use in individuals with conditions such as primary ovarian failure, sex-hormone-dependent neoplasms of the reproductive tract, uncontrolled intracranial lesions, or ovarian enlargement of undetermined origin. Safety and efficacy have not been established in patients with renal or hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information indicates that an overdose of human Chorionic Gonadotropin (hCG), the active substance in Choriomon, is not expected to produce life-threatening symptoms in general. However, the use of gonadotropins carries the risk of Ovarian Hyperstimulation Syndrome (OHSS), which is considered the principal serious adverse reaction and can be life-threatening.

OHSS is a medical event that may progress rapidly. Symptoms of OHSS can range from mild abdominal discomfort to severe manifestations including rapid weight gain, severe abdominal pain and distension, severe nausea, vomiting, decreased urination (oliguria), and shortness of breath (dyspnea). Severe OHSS may be associated with hemoconcentration, electrolyte imbalances, and serious complications like thromboembolic events (blood clots).

When to seek medical help:

  • Seek immediate medical attention or call the Poison Help line if an overdose is suspected.
  • Call your doctor right away if you develop any symptoms of OHSS, such as severe pelvic pain, rapid weight gain, trouble breathing, or severe nausea and vomiting.
  • If serious OHSS occurs, the required emergency action is to stop all gonadotropins, including hCG, and consider whether hospitalization is necessary. Treatment is primarily symptomatic, involving bed rest and managing fluid and electrolyte balance.

Therapeutic Uses of Choriomon

Choriomon is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving episodic or fluctuating manifestations within the reproductive system. The treatment helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

The therapeutic use of chorionic gonadotropin (hCG), the active substance in Choriomon, is commonly used to help with certain distressing symptoms related to fertility issues in both men and women. The treatment is considered relevant for easing symptomatic burden in a few key areas, including induction of ovulation in anovulatory patients, hypogonadotropic hypogonadism in male patients, and prepubertal cryptorchidism.

In clinical scenarios, hCG therapy is applied in addressing symptoms related to physical discomfort that may be associated with these conditions. The goal is to provide support that helps ease the overall symptom burden for patients. As a key principle in supportive care:

“Offers symptomatic relief that helps patients cope more steadily.”

This supports patients during episodes of heightened discomfort and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. Health Canada Product Monograph for Pregnyl (Chorionic Gonadotropin)

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Choriomon?

Choriomon (Choriogonadotropin alfa) is authorized for use in specific populations by regulatory bodies, primarily adult women undergoing treatment for anovulatory infertility or prior to assisted reproductive techniques (ART), and adult men with hypogonadotropic hypogonadism. It is also approved for prepubertal males with cryptorchidism (undescended testicles) not caused by anatomical obstruction.


Contraindications: Populations Who Must Not Use Choriomon

Regulatory documents state that use is strictly contraindicated in several groups. These include patients with a known hypersensitivity to the drug or its components, those with sex-hormone-dependent tumors (such as ovarian, uterine, or prostate), or individuals with Primary Ovarian Failure (indicated by high FSH levels).

Use is also prohibited once pregnancy is established. Further contraindications include active thromboembolic disorders, large ovarian cysts of unknown cause, and certain malformations of the sexual organs incompatible with pregnancy.


Age and Comorbidity Restrictions

The medicine is not established for children under the age of four and is not indicated for postmenopausal women. Caution is advised for patients with a history of thromboembolism or underlying conditions like cardiac disease, renal disease, epilepsy, or migraine, which may be aggravated by the treatment. Use is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Profile: Official Regulatory Information

Classification Official Regulatory Statement
Drug-Drug Interaction Studies None conducted.
Drug/Lab Test Interaction May interfere with specific test results.
Additive Risk Statement Thromboembolic risk can be further increased.

Interacting Substances and Restrictions

Choriomon, which contains the active ingredient Choriogonadotropin Alfa, has a regulatory interaction profile defined by the absence of formal pharmacokinetic interaction data. The official prescribing information explicitly states that no specific drug-drug interaction studies have been conducted to evaluate the effects of co-administered medicines on the exposure (e.g., AUC/Cmax) of Choriomon, or vice-versa. Therefore, no specific medicinal products or food items are listed as strictly contraindicated or requiring timing separation due to metabolic or transporter-mediated interactions.

The official labels document two constraints related to the drug's use:

  • Laboratory Test Interference: Administration of Choriomon may interfere with the immunological determination of serum or urinary human Chorionic Gonadotropin (hCG) and Luteinizing Hormone (LH) for up to ten days post-administration. This interference can lead to a false positive pregnancy test result.
  • Additive Pharmacodynamic Risk: Official caution is provided that treatment with gonadotropins, including Choriomon, may further increase the risk of thromboembolic events in women with pre-existing or generally recognized risk factors for blood clotting disorders.

Connection to the overall interaction profile

The regulatory profile is characterized by the explicit lack of data regarding specific enzyme- or transporter-mediated drug-drug interactions, resulting in no officially documented changes to drug exposure. The primary interaction concerns the potential for lab test interference and an additive risk statement related to the drug's therapeutic class.

Mechanism of Action

Choriomon contains human chorionic gonadotropin (hCG), which functions as an agonist at the luteinizing hormone/choriogonadotropin receptor (LHCGR). This receptor is a G protein-coupled receptor primarily located on ovarian theca and granulosa cells in females, and Leydig cells in males.

Activation of LHCGR by hCG initiates an intracellular signaling cascade predominantly involving the Galphas subunit. This leads to the activation of adenylyl cyclase, which catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP). Increased cAMP levels activate protein kinase A (PKA).

In the ovaries, this downstream cascade stimulates late follicular maturation and the production of gonadal steroids, particularly progesterone from the corpus luteum, thereby sustaining its function. In the testes, the PKA pathway promotes the biosynthesis of androgens, such as testosterone, by stimulating the transcription of steroidogenesis-related genes.

Dosage and Administration Information

How to Use Choriomon (Chorionic Gonadotropin)

The administration of Choriomon (Human Chorionic Gonadotropin or hCG) is restricted to injection and must strictly follow the schedule and dosage prescribed by a healthcare professional based on the specific condition being treated, such as induction of final follicular maturation in fertility treatments or treatment of hypogonadism in males.

Administration Details

Classification Rule Details
Route of Administration Injection Subcutaneous (SC) (under the skin) or Intramuscular (IM) (into a muscle).
Preparation Reconstitution Required Choriomon is supplied as a lyophilized powder and must be dissolved using the designated solvent (diluent) immediately prior to use. Gently agitate the vial until the powder is completely dissolved. Do not shake.
Timing in ART Single Dose For ovulation induction in Assisted Reproductive Technology (ART), a single injection is typically administered 24 to 48 hours after the last dose of a gonadotropin (e.g., FSH or hMG).
Dosing for ART 5,000 to 10,000 IU The standard dose for a single ovulation-triggering injection is 5,000 to 10,000 International Units (IU).
Dosing (Male) Multiple Times Weekly Regimens for hypogonadotropic hypogonadism involve multiple injections (e.g., 500 to 4,000 IU) administered intramuscularly two to three times per week for several weeks or months.

Procedural and Dose Management

Procedural Steps: After reconstitution, the solution must be inspected for particulate matter or discoloration; the solution must then be drawn into the syringe for injection via the prescribed route (SC or IM). Injection sites should be rotated, particularly with subcutaneous self-administration, to avoid irritation.

Missed Dose: If a patient misses a scheduled dose, they must immediately contact their treating physician or clinic for specific guidance; a double dose should not be taken to compensate for the missed one.

Note: Administration of hCG must be withheld if there is evidence of developing ovarian hyperstimulation syndrome (OHSS) prior to the planned injection.

Recent Clinical Evidence

Research evidence / Overview of Studies for Choriomon

The clinical evaluation of Choriomon (choriogonadotropin alfa) is centered on research examining its application in fertility treatment contexts. Research has focused on evaluating its intended action in completing the process of egg maturation and exploring its application as a supportive treatment during the luteal phase of the cycle. The evidence base consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews, which examine it against existing treatments or assess outcomes under controlled conditions.


Evidence for Triggering Final Follicular Maturation and Ovulation

Research explored choriogonadotropin alfa in trials assessing short-term or episodic symptom patterns related to infertility. These studies were conducted on infertile adult women who were already undergoing ovarian stimulation, primarily as part of assisted reproductive technology (ART) protocols. Researchers monitored the number of mature oocytes retrieved and rates of subsequent clinical pregnancy and live birth.

The key research has often involved comparative studies, where choriogonadotropin alfa was evaluated in trials that compared findings with older, urinary-derived Human Chorionic Gonadotropin (hCG) products. Findings describe patterns observed in the studies that were reported as consistent across the reviewed comparative trials. Direct data comparing choriogonadotropin alfa to a placebo for the specific final trigger step is limited, as many pivotal trials aimed to establish equivalence to the older product.


Research on Adjunctive Use for Luteal Support

Choriogonadotropin alfa was studied for its potential role in supporting the luteal phase of the cycle following ovarian stimulation. Research examined temporary physiological imbalance by monitoring hormonal outcomes, such as changes in mid-luteal serum progesterone levels. The trials comparing the use of choriogonadotropin alfa for luteal support against standard progesterone-only protocols reported mixed findings.

Uncertainty remains due to the heterogeneity of the studies. Evidence quality varies across studies because of differing protocols and patient groups. This variability makes it difficult to draw firm conclusions, meaning that certainty remains low regarding the best approach for every individual. The results apply only to the populations studied in the major clinical programs, which typically included adult women within a specific reproductive age range who met strict trial inclusion criteria.

Frequently Asked Questions (FAQ)

Common questions about Choriomon (FAQ)

Q: How long do side effects from Choriomon usually last?

The duration of mild side effects can vary by patient. According to official labeling, signs of Severe Ovarian Hyperstimulation Syndrome (OHSS), a more serious condition, often occur after treatment and may reach maximum severity seven to ten days following the injection. The drug may also interfere with pregnancy tests for up to ten days after the dose.

Q: How quickly does Choriomon start working after an injection?

Choriomon is designed to act as a trigger signal. Following the injection, an increase in the drug’s concentration in the body typically begins within two hours, with peak concentrations reached within about six hours. The drug's primary function is to trigger the final steps of follicular maturation and prompt the body's signal for ovulation.

Q: How long after taking Choriomon can I take a pregnancy test?

The official product information warns that the drug may interfere with standard immunological pregnancy tests for up to 10 days after administration. Because the active ingredient is similar to the hormone measured in pregnancy tests, taking a test during this window could result in a false positive result. Patients are advised to consult with a healthcare professional regarding the optimal timing for a pregnancy test.

Q: Can women with PCOS use Choriomon?

The drug is indicated for use in anovulatory infertile women, meaning women who do not ovulate naturally. Since Polycystic Ovary Syndrome (PCOS) is a common cause of anovulatory infertility, Choriomon may be used as part of a treatment plan. A healthcare provider typically determines if the medication is appropriate based on an individual's specific diagnosis and clinical needs.

Q: What should I do if the Choriomon powder doesn't fully dissolve when mixing?

The product instructions require the solution to be clear and free of any particulate matter or discoloration before use. Official instructions state that if the solution contains particles or is not clear, it should not be used and must be discarded according to proper procedures.

Q: How does Choriomon affect estrogen and testosterone levels?

Choriomon acts on hormone receptors to stimulate the production of gonadal steroids. In females, this includes hormones such as progesterone and estrogen. In males, it stimulates the Leydig cells to produce male sex hormones, specifically testosterone (an androgen).

Q: Does alcohol consumption affect the effectiveness of Choriomon?

Official prescribing information indicates that no formal drug-drug interaction studies, including specific studies with alcohol or food, have been conducted. Any use of alcohol during the treatment period is best reviewed with a healthcare professional.

Q: Is Choriomon safe to use if I have thyroid problems?

Official labeling advises that patients should be evaluated for, and provided appropriate treatment for, any uncontrolled non-gonadal endocrine disorders. This includes thyroid disorders. This measure helps ensure that uncontrolled conditions, such as thyroid disorders, do not complicate the fertility treatment.

Q: Can Choriomon interact with common pain relievers like ibuprofen?

The official prescribing information explicitly states that no specific drug-drug interaction studies have been conducted to evaluate its effects with other medicines. The use of this medication with other non-prescription drugs, like ibuprofen, should be reviewed with a healthcare professional.

Q: Are there any foods or supplements that should be avoided while taking Choriomon?

No specific food items or supplements are listed as strictly contraindicated in the official prescribing information, as formal interaction studies are lacking. Patients are advised to discuss their use of diet, vitamins, and supplements with a healthcare provider.

Q: Does Choriomon affect male fertility?

The drug is indicated for use in adult men with hypogonadotropic hypogonadism to stimulate androgen production. The treatment can help stimulate sperm production (spermatogenesis) in selected cases, which may support improved fertility outcomes.

Q: What is the difference between Choriomon and other brands of HCG?

Choriomon contains the active ingredient Choriogonadotropin Alfa, which is a recombinant (synthetic) hormone. This recombinant origin differentiates it from older Human Chorionic Gonadotropin (hCG) products, which were derived by extracting the hormone from human urine.

Q: Does Choriomon cause weight gain?

Weight gain is listed in the official labeling as a characteristic feature of Severe Ovarian Hyperstimulation Syndrome (OHSS), a potentially serious side effect. Rapid weight gain, swelling of the extremities (ankles, hands, or feet), and other concerning symptoms should be reported to the prescribing clinic.

Q: What happens to the Choriomon in the body after it has done its job?

The drug is naturally metabolized and cleared by the body. The levels of the active ingredient decline in the blood over time, with the terminal phase half-life reported between 23 and 37.2 hours. It is eventually excreted, with a small portion of the dose excreted in urine.

Q: Can Choriomon interact with birth control pills?

The official prescribing information explicitly states that no specific drug-drug interaction studies have been conducted. The use of this medication concurrently with other hormone-containing medications, such as birth control, should be reviewed by a healthcare professional.

Q: Why is it important to time the Choriomon shot exactly as directed?

The timing is critical because the injection is meant to mimic the body’s natural Luteinizing Hormone (LH) surge. This surge is the signal that triggers the final step of maturation and the release of the egg. The precise schedule is essential for successful egg retrieval or planned intercourse.

Q: Can Choriomon interact with antidepressant medications?

The official prescribing information explicitly states that no specific drug-drug interaction studies have been conducted. Patients are advised to inform their healthcare professional of any antidepressant or other medications they are currently taking.

Q: What is the half-life of Choriomon in the body?

Pharmacokinetic data shows that the terminal phase half-life of the active ingredient, Choriogonadotropin Alfa, has been reported to be between 23 and 37.2 hours. The half-life refers to the time it takes for the amount of drug in the body to be reduced by half.

Q: Is it safe to exercise heavily after receiving a Choriomon injection?

Official labeling warns of the risk of Ovarian Hyperstimulation Syndrome (OHSS). Patients may be advised to avoid strenuous activity, particularly physical exercise, in the context of OHSS due to a potential risk of complications.

Q: Can I drive after taking Choriomon?

Official regulatory information does not specifically caution against driving. However, side effects such as headache, tiredness, and dizziness have been reported. If these effects are experienced, caution should be used when driving or operating machinery.

Q: What is the difference in packaging for Choriomon for men vs. women?

The product is supplied as a powder for injection that must be reconstituted (mixed). While the required dosage and the frequency of use differ significantly between men and women, the official labels describe the product's vial and kit presentation, which is typically standard regardless of the patient's sex.

Q: Is Choriomon sold over the counter anywhere?

No. Choriomon is classified as a prescription medicine ('Rx only') by regulatory bodies and cannot be obtained without a valid prescription from a licensed healthcare provider.

Q: What is the correct way to dispose of used Choriomon needles and vials?

Used needles and syringes must be immediately placed in a closeable, puncture-resistant sharps container. Unused medicine and the original vials should not be thrown in household trash or down the drain. They are typically disposed of at an approved collection center, in accordance with local environmental and biohazard regulations.

Q: Can Choriomon be used by women who have already gone through menopause?

No, according to the official labeling. The safety and effectiveness of the drug have not been established in and it is not indicated for use in postmenopausal women.

Q: How does the purity of Choriomon compare to other HCG products?

Choriomon's active ingredient, Choriogonadotropin Alfa, is a recombinant (synthetic) protein. This manufacturing process ensures the product has a high level of purity and consistency compared to older chorionic gonadotropin products that were naturally derived by extracting the hormone from human urine.

Q: Is it common to feel tenderness in the breasts after a Choriomon injection?

Breast pain is listed as an uncommon side effect in the official product labeling. However, other symptoms associated with hormonal changes, such as breast tenderness or swelling, have also been reported by patients using the active ingredient.

Q: Can Choriomon make you feel tired or dizzy?

Yes, official safety documents list tiredness (fatigue) as a common side effect. Although less frequent, dizziness has also been reported as an adverse reaction to the medication.

How should Choriomon be stored and disposed of?

Storage and Disposal of Choriomon

Storage of Choriomon (Chorionic Gonadotropin) is strictly defined by its physical state to maintain labeled stability.


Storage Conditions

Product State Temperature Requirement
Unreconstituted Powder Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), protected from heat, moisture, and light.
Reconstituted Solution Refrigerate at 2 C to 8 C (36 F to 46 F). Do not freeze.

Stability and Safety: The reconstituted solution must be used within a limited period (e.g., 30 or 60 days) when continuously refrigerated. Keep the medicine out of the reach of children and pets in its original container.


Disposal Instructions

Used needles and syringes must be placed in a closeable, puncture-resistant sharps container. This container must be taken to an approved collection center for disposal according to local regulations. Do not throw sharps or unused medicine in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Choriomon found in:

A-Z Index: